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Background: In search of new antiparasitic agents for overcoming the limitations of current leishmaniasis chemotherapy,
we have previously shown that 6-bromoindirubin-3'-oxime (6BIO) and several other 6-substituted analogues of indirubin,
a naturally occurring bis-indole present in mollusks and plants, displayed reverse selectivity from the respective mammalian
kinases, targeting more potently the leishmanial Cyclin-Dependent Kinase-1 (CDK1) homologue [cdc2-related protein
kinase 3 (LCRK3)] over leishmanial Glycogen Synthase Kinase-3 (LGSK-3). This reversal of selectivity in Leishmania
parasites compared to mammalian cells makes the design of specific indirubin-based LGSK-3 inhibitors difficult. In this
context, the identification of compounds bearing specific substitutions that shift indirubin inhibition towards LGSK-3,
previously found to be a potential drug target, over LCRK3 is imperative for antileishmanial targeted drug discovery.
Methods: A new in-house indirubin library, composed of 35 compounds, initially designed to target mammalian
kinases (CDKs, GSK-3), was tested against Leishmania donovani promastigotes and intracellular amastigotes using
the Alamar blue assay. Indirubins with antileishmanial activity were tested against LGSK-3 and LCRK3 kinases, purified
from homologous expression systems. Flow cytometry (FACS) was used to measure the DNA content for cell-cycle
analysis and the mode of cell death. Comparative structural analysis of the involved kinases was then performed
using the Szmap algorithm.
Results: We have identified 7 new indirubin analogues that are selective inhibitors of LGSK-3 over LCRK3. These
new inhibitors were also found to display potent antileishmanial activity with GI50 values of <1.5 μΜ. Surprisingly,
all the compounds that displayed enhanced selectivity towards LGSK-3, were 6BIO analogues bearing an additional
3'-bulky amino substitution, namely a piperazine or pyrrolidine ring. A comparative structural analysis of the two
aforementioned leishmanial kinases was subsequently undertaken to explain and rationalize the selectivity trend
determined by the in vitro binding assays. Interestingly, the latter analysis showed that selectivity could be correlated
with differences in kinase solvation thermo dynamics induced by minor sequence variations of the otherwise highly
similar ATP binding pockets.
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Conclusions: In conclusion, 3'-bulky amino substituted 6-BIO derivatives, which demonstrate enhanced specificity
towards LGSK-3, represent a new scaffold for targeted drug development to treat leishmaniasis.
Keywords: Leishmania, Indirubins, LGSK-3, Szmap, Binding site solvationBackground
Leishmaniasis is a vector-borne neglected tropical disease
caused by parasitic protozoa of the genus Leishmania [1].
Mammals, including humans, are infected by Leishmania
promastigote parasites via the bite of female phlebotomine
sand flies [2,3]. After Leishmania promastigotes pass into
the mammalian blood, they are phagocytosed by macro-
phages and once located within the macrophages’ phago-
lysosomes, promastigotes transform into the non-motile
amastigote form and multiply [4]. More than 350 million
people are at risk of Leishmania infection and about 1.5-2
million new cases and 500,000 deaths are considered to
occur every year in the endemic areas [1]. The increasing
resistance of Leishmania parasites and the toxicity of the
current therapy as well as the non-existence of a human
vaccine, generate an urgent need to discover effective, new-
targeted drugs for treating leishmaniasis [5,6]. Research
on natural products has been proved to be promising
for discovering new lead structures in a variety of diseases
including leishmaniasis [6]. Amongst natural product scaf-
folds, alkaloids display considerable structure diversity that
can be exploited for the discovery of novel antileishmanials
[6]. Moreover, marine indole-based alkaloid scaffolds [7]
like variolin [8], roscovitine [9], leucettines [10] and haloge-
nated indirubins [11], known to target kinases, represent a
significantly large pool of compounds for the discovery of
new targeted antileishmanial treatment [12,13].
Specifically, indirubin is a naturally occurring bis-indole
found in different species like indigo-bearing plants (Isatis
spp., Polygonum spp.) or marine organisms (Murex shellfish
family, Hexaplex trunculus) [11]. It has been identified as a
potent inhibitor of protein kinases (CDKs) [14], whereas
naturally halogenated indirubins such as 6-bromoindirubin
(6BI) demonstrate selective inhibitory activity towards
the mammalian Glycogen-Synthase Kinase-3 (GSK-3) [15].
The semi-synthetic analogue of 6BI, 6-bromoindirubin-
3′-oxime (6BIO) was developed as a potent and selective
GSK-3β inhibitor and is currently considered as one
prototype inhibitor of that mammalian kinase [16].
The Cyclin-Dependent Kinase1 (CDK1) homologue of
Leishmania [cdc2-related protein kinase 3 (LCRK3)] and
the glycogen synthase kinase-3short (LGSK-3) have emerged
amongst other kinases as putative molecular drug targets
for the treatment of leishmaniasis [13,17-20]. LCRK3 was
characterized by genetic analyses as an essential protein
for parasite viability and a central regulator of cell-cycle
progression [21]. Inhibition of LCRK3 in Leishmania para-sites resulted in a G2/M cell-cycle arrest, which was subse-
quently followed by an apoptosis-like death of the parasites
[13,21]. Recently, the trypanosomatid GSK-3 was identified
as a potential drug target for treatment of parasitic diseases
[13,19]. In a previous study, we showed that LGSK-3 was
essential for parasitic viability, and its inhibition caused
cell-cycle defects and apoptosis-like death [13]. We have
previously shown that 6-substituted indirubin analogues,
including 6BIO, inhibit more potently LCRK3 than LGSK-
3, a reverse selectivity compared to the corresponding
mammalian homologues. The only exceptions to this
reversal were the bisubstituted 5-methyl-6-bromoindiru-
bin-3′-oxime (5-Me-6BIO) which was 7-fold more selective
towards LGSK-3 over LCRK3 and 6-bromoindirubin-3′-
acetoxime (6-BIA) which inhibited both kinases equally
well [13]. This reversal indicated that the mammalian
GSK-3/CDK1 selectivity determinants differ from the
corresponding parasitic ones. Herein, we describe the
evaluation of indirubin analogues, initially designed to
target mammalian kinases, against Leishmania parasites.
One main objective of this study was to improve indirubin
selectivity towards LGSK-3 over LCRK3. This knowledge
is important for antileishmanial drug discovery since
previous studies showed that LCRK3 inhibition did not
translate very well into antiparasitic activity [18,22]. In
addition, this knowledge is anticipated to be crucial for
Structure Activity Relationship studies (SARs) and modifi-
cation of the lead compound to more potent and specific
inhibitor. Overall, this approach led to the identification of
indirubin based antileishmanial agents favoring inhibition
of LGSK-3 over LCRK3. Interestingly, the compounds
with LGSK-3 specificity were 6BIO derivatives possessing
bulky amino substitution namely a piperazine or pyrroli-
dine ring at position 3′, suggesting that these substitutions
increase the affinity of the compound towards LGSK-3
but not towards LCRK3. A comparative structural analysis
of the two aforementioned parasitic kinases was under-
taken as a means to explain and rationalize the selectivity
trend determined by in vitro assays, showing that the en-
hanced selectivity of 6-bromo-3′-substituted indirubins
for LGSK-3 can be attributed to differences in the solv-
ation pattern of the otherwise similar ATP binding pocket.
Methods
Chemical synthesis
The studied compounds have been synthesized according
to the methodology developed previously [11,16,23,24].
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against L. donovani promastigotes and intracellular
amastigotes in vitro
All compounds were dissolved in DMSO at 10 mM and
serial dilutions in DMSO were made (1 mM and 100 μM).
The analogues were further diluted in the culture medium
to give the desired final concentrations.
The antileishmanial activity was determined using
the Alamar blue assay [25]. L. donovani promastigotes
(MHOM/ET/0000/HUSSEN) which were frequently passed
in BALB/c mice [26] were used in all experiments. Specific-
ally, 2.5×106 cells/ml of L. donovani promastigotes in the
stationary phase were seeded into 96-well flat bottom plates
in total volume of 200 μl M199 without phenol red per
well. In triplicates, indirubins were added in increasing
concentrations and equivalent volumes of the solvent
DMSO (<0.1%v/v) were used as control. After incuba-
tion of the parasites for 72 hrs at 26°C, Alamar blue
(20 μl/well) was added for a further 24 hrs and colorimetric
changes were read at 550 nm with reference wavelength
620 nm. Calculation of the compound concentration that
induces 50% reduction of the growth rate of the pro-
mastigotes (GI50 values for 50% growth inhibition) was
performed using the parasites treated with DMSO as
control growth rate sample. GI50 values were determined
from dose–response curves via linear interpolation.
For the in vitro infection evaluation of indirubins’
antileishmanial activity, 2×105 J774.1 cell line macrophages
per ml in 200 μl RPMI supplemented with 10% (v/v) HIFBS
(heat-inactivated fetal bovine serum), 10 mM HEPES and
penicillin-streptomycin (final concentration 100U ml−1),
were seeded into 96-well flat bottom plates. The macro-
phages were left to adhere overnight at 37°C in an atmos-
phere of 5% CO2. Afterwards, the macrophage infection
was performed at a ratio of 10 parasites/macrophage for
24 hrs at 37°C in 5% CO2, followed by the incubation of
the infected macrophages with the indirubins for 72 hrs.
DMSO-treated macrophages, which were infected with
parasites, were used as controls. After this 72 hrs period
and the removal of the medium, the macrophages were
lysed with 100 μl 0.01% (v/v) SDS in PBS for 30 min at
37°C. Then, 100 μl Schneider’s medium was added to
each well and amastigote growth was assessed by the
addition of Alamar blue (20 μl/well) and the plates were
incubated for 48 hrs at 37°C [27]. Calculation of the
GI50 values was performed as previously described [13].
In order to confirm the in vitro infection evaluation
results of indirubins’ antileishmanial activity, we also
performed the assay with 2×105 peritoneal macrophages,
collected from BALB/c mice (4–6 weeks old), 72 hrs
after the intraperitoneally administration of 1 ml sterile
thioglycollate medium (4% w/v, Becton Dickinson, Sparks,
MD, USA). The mice, which were used with prior approval
by the Animal Bioethics Committee of the Hellenic PasteurInstitute (HPI; Athens, Greece) according to the Directive
2010/63/EE of the council of Europe, for the protection of
vertebrates/animals, were euthanized for the recovery of
peritoneal macrophages. The peritoneal macrophages were
centrifuged (1,200 rpm, 4°C, 10 min) and washed 3 times
with RPMI-1640 medium. After the collection of the peri-
toneal macrophages the steps followed were the same as
the ones described above for the in vitro infection assay
with J774.1 cell line macrophages.
For the compounds 11–17, the intracellular amastigote
assay was performed at first with both murine macrophagic
cell-line J774.1 and peritoneal macrophages extracted
from BALB/c mice. The results from both assays were
significantly similar (data not shown) and therefore the
following experiments were performed with J774.1 murine
macrophages.
Cell-cycle and cell-death analysis of indirubin-treated
promastigotes by flow cytometry
L. donovani promastigotes in the stationary phase
(2×107cells/ml) were seeded at 106cells/ml in M199
medium and incubated for 48 hrs, at 26°C with the
GI50 concentration of each analogue or with DMSO, as
control. For the analysis of the cell cycle, the procedure
described in Georgopoulou et al. [28], was followed to
prepare the samples for fluorescence-activated cell sorting.
In order to determine the amount of cells, which display
membrane fluidity perturbations, FACS analysis was per-
formed using AnnexinV-FITC and propidium iodide (PI)
staining (Apoptosis Detection kit, R & D Systems). All sam-
ples were analyzed using a Becton Dickinson FACS Calibur
flow cytometer and data were analyzed using the Cell Quest
software. All experiments were performed in triplicates.
Kinase assays
Recombinant LGSK-3 and LCRK3 were produced and
purified from L. donovani over-expressing transfectants
and transgenic L. mexicana promastigotes respectively, as
previously described [13]. LCRK3 expressing L. mexicana
parasites were a kind gift from Dr. K. Grant. The Kinase
Luminescent Assay Kit (Promega) was used to perform
the kinase assays, following the manufacturer’s instruc-
tions as previously described [13]. For determining the
kinase activity of LGSK-3, GS-1 peptide was used as a sub-
strate (YRRAAVPPSPSLSRHSSPHQSpEDEEE) [29] while
LCRK3 kinase assays were performed using histone H1 as
a substrate [18], with increasing concentrations of each
compound. IC50 values (μM) were determined from dose–
response curves. All experiments were performed in
triplicates.
Computational analysis
Homology models were built for LGSK-3 and LCRK3
of three Leishmania species (L. major, L. donovani, L.
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O96526, Q7K8Z1, A4ICT0) using Prime 3.1 and the
corresponding cocrystal structures of human GSK-3
and CDK5 with indirubin (pdb codes 1UV5, 1UNH) as
templates [30]. Computational analysis of protein solvation
was performed using Szmap algorithm. Szmap implements
a semi-continuous solvation model for mapping the
surface of the protein and identifies hydration sites of
positive (unstable) and negative (stable) free energy.
Characterization of water molecules according to their
free energy permits rational design of high affinity ligands,
which either displace unstable waters or replace stable
waters by polar groups of similar capability for accom-
modating electrostatic interactions with the protein.
Results and discussion
In order to understand which specific substitutions on
the indirubin analogues contribute to LGSK-3 selectivity,
we evaluated a larger collection of indirubin analogues
designed to target several mammalian kinases including
CDKs and GSK-3, with pleiotropic substitutions in the
indirubin backbone (Table 1). The indirubin scaffold was
substituted with various functional groups, interventions
initially designed for effective inhibition of mammalian
GSK-3 [23]. Those 6BIO analogues bear bulky and
hydrophilic amino chains in position 3′ aiming at the
enhancement of the otherwise low indirubin water-
solubility. To this end, we screened this set against L.
donovani promastigotes (the insect form) and intracellular
amastigotes (the form found in mammals) at 3 μM
(Table 1). Their toxicity against the murine macrophagic
cell-line J774.1 was assessed at 10 μΜ (Table 1). This ini-
tial screening showed that 9 out of 35 analogues, were able
to induce 100% growth inhibition when tested against L.
donovani promastigotes form at 3 μΜ. Both forms of the
studied 6BIO analogues (free base and hydrochloride salt)
were tested yet only one pair of compounds presented
a small difference in activity (salt 11 was found active
against L. donovani promastigotes compared to its cor-
responding base 10 which was inactive at 3 μΜ). This
minor discrepancy can be attributed to differences in
cell permeability between the two forms of the com-
pound. Indeed, 10 is the only analogue possessing a
non-substituted piperazine group and thus demonstrates
a higher pKa (≈1 unit) value. This physicochemical param-
eter could have an effect on the overall solubility of 10
at the pH of culture media, resulting to the observed
difference in activity. Such discrepancies between free
base and corresponding salt forms have been described
in previous studies reporting activity of antitrypanoso-
mal agents against parasites [31]. Compounds 4 and 5
that were active against L. donovani promastigotes, with a
GI50 of 1.15 ± 0.06 and 0.9 ± 0.11 respectively, were found
to be toxic to the murine macrophagic cell-line J774.1(GI50: 1.5 ± 0.07 and 1.5 ± 0.08 respectively). Thus, these
compounds were not further studied for their activity
against intracellular amastigotes. Subsequently, GI50
values (μM) of compounds 11–17 for both L. dono-
vani promastigote and amastigote forms were determined.
Indirubin analogues possessing halogeno groups (Br, CF3)
in position 7 had no significant effect on L. donovani
promastigote (GI50 > 3 μΜ) and intracellular amastigote
growth (GI50 > 3 μΜ) (Table 1). On the contrary, the 3′-
amino chain substituted 6BIO analogues 11–17 displayed
antileishmanial activity against promastigotes at the low
micromolar or nanomolar range (GI50: 0.65-1.50 μΜ).
For these compounds, the intracellular amastigote assay
was performed. Notably, the GI50 values obtained (GI50:
0.59-2.44 μΜ) were in the same range with the previ-
ously reported values of 6BIO and 5-Me-6-BIO [13].
The analogues 11–15 shown in Table 1 inhibited the L.
donovani promastigotes and intracellular amastigotes
equally well. Derivatives 16 and 17 inhibited the promasti-
gotes with a GI50 of 0.76 ± 0.03 μΜ and 0.76 ± 0.04 μΜ
respectively, but their inhibitory effects against intracellu-
lar amastigotes were slightly lower (GI50: 1.54 ± 0.11 μΜ
and 1.22 ± 0.06 μΜ respectively). Interestingly, com-
pounds 11 and 17 displayed a good selectivity index (>8)
over the murine macrophagic cell-line J774.1, which was
used to assess indirubin cytotoxicity (Table 1).
Next, we selected the indirubin analogues with antil-
eishmanial activity (11–17) to evaluate their inhibitory
effect towards LGSK-3 and LCRK3 kinases. In addition,
to confirm that the selection of the compounds was
unbiased, we selected several indirubins with no antil-
eishmanial activity (compounds 2, 27, 30, 33) to perform
the kinase assay. The parasitic kinases (LGSK-3 and
LCRK3) were purified from homologous expression
systems as previously described [13,18]. The Km values of
both kinases for ATP and their respective substrate were
in accordance to those previously reported [13]. The IC50
values were calculated from the dose–response curves.
6BIO and 5-Me-6-BIO [13] were tested in parallel and
were used as reference controls. Interestingly, results
obtained using in vitro assays against LGSK-3 and LCRK3
kinases, showed that the 6BIO analogues substituted with
a piperazine or pyrrolidine ring at position 3′shifted the
6BIO selectivity towards LGSK-3 (Table 2). On the other
hand, the selected analogues with no antileishmanial activ-
ity (compounds 2, 27, 30, 33), did not display any relevant
activity towards LGSK-3 or LCRK3 (IC50 > 3.33 μΜ) (data
not shown).
Thus, herein (Table 2), we showed that the 7-fold se-
lectivity displayed by 6BIO towards LCRK3 over LGSK-3
was shifted to LGSK-3 over LCRK3 selectivity upon the
incorporation of a nitrogen-containing saturated ring in
position 3' of the indirubin core. This type of substitu-
tion could enhance the affinity of the scaffold towards
Table 1 Inhibitory activity of the studied indirubin analogues against L. donovani promastigotes and intracellular
amastigotes
L. donovani (GI50 μM)
Cpd Y R1 R2 R3 R4 R5 R6 Promastigotes Intracellular amastigotes ΜΦ J774.1 (GI50 μM)
1 NO H Br H H H >3 μΜ >3 μΜ -
2 NO H Br H H H >3 μΜ >3 μΜ -
3 NO H Br H H H >3 μΜ >3 μΜ -
4 NO H Br H H H 1.15 ± 0.06 - 1.5 ± 0.07
5 NO H Br H H H 0.9 ± 0.11 - 1.5 ± 0.08
6 NO H Br H H H >3 μΜ >3 μΜ -
7 NO H Br H H H >3 μΜ >3 μΜ > 10
8 NO H Br H H H >3 μΜ >3 μΜ >10
9 NO H Br H H H >3 μΜ >3 μΜ >10
10 NO H Br H H H >3 μΜ >3 μΜ > 10
11 NO H Br H H H 0.75 ± 0.05 0.59 ± 0.07 6.25 ± 0.08
12 NO H Br H H H 0.65 ± 0.09 0.80 ± 0.12 2.60 ± 0.05
13 NO H Br H H H 0.82 ± 0.21 0.85 ± 0.16 2.41 ± 0.11
14 NO H Br H H H 1.40 ± 0.10 1.71 ± 0.09 9.20 ± 0.15
15 NO H Br H H H 1.50 ± 0.14 2.44 ± 0.17 6.00 ± 0.08
16 NO H Br H H H 0.76 ± 0.03 1.54 ± 0.11 5.93 ± 0.04
17 NO H Br H H H 0.76 ± 0.04 1.22 ± 0.06 10.00 ± 0.02
18 NO H Br H H H >3 μΜ >3 μΜ -
19 NO H Br H H H >3 μΜ >3 μΜ -
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Table 2 Inhibition of L. donovani LGSK-3 and L. mexicana
LCRK3 by compounds 11–17
IC50 (μM)
Compounds LGSK-3 LCRK3
6-BIO 0.15 ± 0.06 0.02 ± 0.01
5-Me-6-BIO 0.09 ± 0.02 0.65 ± 0.09
11 0.10 ± 0.07 >3.33
12 0.20 ± 0.08 0.99 ± 0.19
13 1.65 ± 0.17 >3.33
14 1.95 ± 0.11 >3.33
15 0.17 ± 0.25 0.14 ± 0.06
16 0.36 ± 0.18 >3.33
17 0.88 ± 0.26 >3.33
Inhibitory kinase activity of the controls 6BIO and 5-Me-6-BIO is also shown.
IC50 values are expressed in μΜ.
Table 1 Inhibitory activity of the studied indirubin analogues against L. donovani promastigotes and intracellular
amastigotes (Continued)
20 O H H Br H H - >3 μΜ >3 μΜ -
21 NO H H Br H H H >3 μΜ >3 μΜ > 10
22 O H H Br COOH H - >3 μΜ >3 μΜ -
23 NO H H Br COOH H H >3 μΜ >3 μΜ -
24 O H H Br H COOH - >3 μΜ >3 μΜ -
25 NO H H Br H COOMe H >3 μΜ >3 μΜ -
26 NO H H Br H COOH H >3 μΜ >3 μΜ -
27 NO H H CF3 H H H >3 μΜ >3 μΜ -
28 NO H H CF3 COOMe H H >3 μΜ >3 μΜ -
29 O H H CF3 COOH H - >3 μΜ >3 μΜ -
30 NO H H CF3 COOH H H >3 μΜ >3 μΜ -
31 O H H CF3 H COOH - >3 μΜ >3 μΜ -
32 NO H H CF3 H COOMe H >3 μΜ >3 μΜ > 10
33 NO H H CF3 H COOH H >3 μΜ >3 μΜ -
34 O H H CF3 H - >3 μΜ >3 μΜ -
35 NO H H CF3 H H >3 μΜ >3 μΜ -
6BIO NO H Br H H H H 0.85 ± 0.05 0.70 ± 0.10 >25
5-Me-6-BIO NO CH3 Br H H H H 1.2 ± 0.2 1.0 ± 0.1 >25
Amphotericin B - - - - - - - 0.10 ± 0.01 0.20 ± 0.02 -
GI50 (μΜ) of compounds tested in vitro for their antileishmanial activity against L. donovani promastigotes and intracellular amastigotes, and their cytotoxicity
against murine macrophages J774.1. GI50 (μΜ) of the controls Amphotericin B, 6-BIO and 5-Me-6-BIO is also shown. Inhibitory activity was evaluated using the
Alamar blue assay, as previously described. GI50 values were determined from dose–response curves via linear interpolation.
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making these analogues more selective. As shown in
Table 2, compound 11 which possesses only an additional
piperazine ring substitution, displays a >33-fold degree of
selectivity for LGSK-3 over LCRK3. These results indicate
that the substitution of the oxime in position 3′ is an im-
portant feature for LGSK-3 inhibition. This finding is con-
sistent with our previous observation that 6BIA inhibited
LGSK-3 more potently [13].
In order to evaluate if the in vitro results of the shifted
LGSK-3 over LCRK3 selectivity displayed by the ana-
logues 11 and 17, are also mirrored in cellulo, we have
further examined their effect on the cell-cycle progres-
sion and the induction of parasitic cell-death. To this
end, we have analyzed the cell-cycle progression in the
L. donovani promastigotes after 24 and 48 hrs treatment
with the compounds 11 and 17. Indirubins were used at
the GI50 concentration. 5-Me-6BIO and 6BIO, known to
induce cell-cycle arrest in the G1 phase by inhibiting
LGSK-3 and G2/M arrest by inhibiting LCRK3 respect-
ively [13], were tested in parallel (Figure 1). Herein, L.
donovani promastigotes treated with compounds 11 and
17 resulted in a rapid increase in the percentage ofsubG0/G1 cells (Figure 1). Cells treated with vehicle only
[0.02% (v/v) DMSO], which were used as negative con-
trol, showed a normal distribution of the cell-cycle at
all time-points studied (Figure 1). These results were in
accordance with the distribution of the selective LGSK-
3 inhibitor 5-Me-6-BIO, which served as a model
Figure 1 Cell-cycle analysis of indirubin-treated cells by flow cytometry. DNA content of parasites treated with vehicle only (A, control,
DMSO < 0.1%) and parasites treated with GI50 concentration of compounds 11 (D), 17 (E). Compounds 6BIO (B) and 5-Me-6-BIO (C) were used
as controls. The DNA content was measured by staining cells with propidium iodide (PI) and the cell-cycle status was analyzed by flow cytometry.
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Figure 2 (See legend on next page.)
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Figure 2 Effect of indirubin analogues 11 and 17 on the cell-death of L. donovani promastigotes. Effect of compounds 11 (B) and 17
(C) on the cell-death of L. donovani promastigotes, incubated with the GI50 of each compound for 48 hrs. Cells were stained with AnnexinV-FITC
(horizontal axis, FL1-H) and propidium iodide PI (vertical axis, FL2-H) to assess membrane fluidity perturbations (AnnexinV staining) and membrane
impermeability. The samples were then analyzed by flow cytometry. DMSO was used as negative control (A).
Figure 3 Multiple sequence alignment of GSK-3 and CRK3 from three related Leishmania species. The multiple sequence alignment depicts
the high homology between GSK-3 and CRK3 of three Leishmania species, namely L. donovani, L. infantum and L. major (Uniprot codes:
A6N857, A4HXQ3, Q4QE15 for GSK-3 and Q4K8Z1, A4ICT0, Q96526 for CRK3, respectively). The gatekeeper positions as well as the three non-conserved
residues of the ribose sub-site are highlighted by green stars and the glycine-rich loop is marked by a green bracket. Alignment was performed using
ClustalW with default settings and the depiction was prepared using ESPript software (http://espript.ibcp.fr) [37,38].
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the accumulation in subG0/G1 phase [13]. In addition,
the contribution of 11 and 17 to the mode and timing
of cell-death was tested. Thus, apoptotic-like cell-death
was assessed by measuring membrane fluidity perturb-
ation and membrane impermeability, until the late stages
of the process. Double staining assay with AnnexinV-
FITC and PI was used, which allows the differentiation
between early apoptotic (AnnexinV-FITC positive), late
apoptotic (AnnexinV-FITC and PI positive), necrotic (PI
positive) and viable cells (unstained) [32-36]. Incubation
of cells with 0.02% (v/v) DMSO showed negative staining
for both AnnexinV and PI, as 93% of the cells were viable
at all time-points (Figure 2). Compounds 11 and 17
caused a rapid increase of late apoptotic or necrotic cellsFigure 4 Comparison of the binding pocket entrance hydration sites
LGSK-3 and LCRK3. Hydration sites with positive free energy as determine
ribbon representation of the protein. The hydration sites are connected wi
be formed between them and neighboring residues. The depicted hydration
like those of compounds 11 and 17. Displacement and release of those water
anticipated entropic gain. A) In LGSK-3, the indirubin substituent of position 3
of the protein hydration shell. B) In LCRK3, the corresponding cluster of unsta
region occupied by the 3' substituent. As a result, binding affinity is not expect
that differ between LGSK-3 and LCRK3 active sites are shown in stick represent
ribbon fragments corresponding to the glycine-rich loop are colored green. Th
on the 6BIO binding pose. For reasons of clarity and given that the poses of 11
Figure 4A and inhibitor 17 in Figure 4B.after 48 hrs of incubation in the parasites (late apoptotic
cells: 42% and 28% respectively, necrotic cells: 5.42%
and 4.28% respectively). These results are in agreement
with the mode of cell death caused by 5-Me-6-BIO and
LGSK-3 inhibition as 48 hrs treatment with the compound
resulted in an increase of the late apoptotic population [13].
On the other hand, parasites incubated with the LCRK3
inhibitor 6BIO, displayed an equal increase on early and
late apoptotic cells [13], different to the cell-death pattern
induced by compounds 11 and 17 displayed. In general,
the above observations strengthen our results and suggest
that the selectivity of the compounds 11 and 17 towards
LGSK-3 is also mirrored in the parasite.
To better explain this shift towards LGSK-3, we per-
formed a comparative structural analysis of LGSK-3 andas mapped using Szmap algorithm between the leishmanial
d by Szmap computational analysis are depicted as red spheres in a
th green lines depicting potential hydrogen bond networks that could
sites potentially overlap with the bulky 3'-substituents of 6BIO analogues
molecules by the compounds would favor binding affinity through the
' occupies a region which overlaps with several unstable water molecules
ble water molecules is smaller and has a markedly lower overlap with the
ed to be affected seriously by their displacement. In both figures, residues
ation and labelled (numbering based on L. donovani sequences). The
e poses of analogues 11 and 17 are depicted as semi-transparent overlays
and 17 are highly similar for each kinase, inhibitor 11 is depicted only in
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species (L. major, L. donovani, L. infantum) [37,38]. Initial
results showed that the active site residues demonstrated
a high degree of sequence conservation within the
group of studied homologues, with the most important
differences being the replacement of the gatekeeper
M100LGSK-3 to F99LCRK3. However, several variations
were located at the vicinity of the binding pocket of the
three LGSK-3/LCRK3 pairs and primarily on the glycine-
rich loop and at the ribose and phosphate binding sub-
sites of the kinases. In LGSK-3 the Gly-loop motifs is
27GQGTFG32 while in LCRK3 it is 30GEGTYG35. At the
ribose site, T106LGSK-3 is replaced by D105LCRK3, while at
the phosphate site H155LGSK-3 is replaced by A149LCRK3
and C169LGSK-3 by A162LCRK3. Those variations were
identified as of possible importance with respect to the
determination of the binding pocket hydration pattern.
Moreover, it was suggested that differences in hydration
could be indirectly induced through the sequence varia-
tions located at the glycine-loop by affecting its flexibility,
which in turn might influence the interaction of the loop
with the water molecules solvating the ribose and phos-
phate sub-sites.
To assess that effect, the computational mapping of the
hydration sites over the surface of the studied kinases
was performed using Szmap algorithm [39,40]. Analysis
of the hydration showed a pronounced difference on
the predicted thermodynamic properties of water mole-
cules, which would be expected to form the first hydra-
tion shell close to the ribose and phosphate binding
sub-sites of each protein. More specifically, a cluster of
waters of positive free energy is present at the afore-
mentioned locations in the LGSK3 structures but not in
the LCRK3 homologues (Figure 4). This cluster defines
an area at which substitution of the solvent by polar lig-
and groups would favor binding affinity while replace-
ment by hydrophobic groups would instead affect affinity
in an unfavorable manner. Given the well-known impact
of protein desolvation on binding affinity, it was hypothe-
sized that compounds that bind the kinases through
specific interactions accommodated at that specific part
of the cavity could have a different affinity among the
otherwise highly similar active sites of LGSK-3 and
LCRK3.
Consistent with this hypothesis is the fact that the 6-
bromo-3′-nitrogen-substituted analogues identified as
lead molecules in the L. donovani growth inhibition
assay, shifted their selectivity towards LGSK-3 over
LCRK3 (11–17, Table 1). Those analogues could selectively
target LGSK-3 by binding adjacent to the aforementioned
region of the pocket, overlapping with the hydration sites of
interest and thus gaining affinity due to the entropic effect
of displacing relatively unstable water molecules from the
kinase first hydration shell.Conclusions
In conclusion, the present study describes the screening of
a small and diverse indirubin library for compounds with
activity inhibiting the growth of leishmanial parasites and
the identification of a class of 3′-bulky amino substituted
indirubin analogues displaying inhibition and specificity
on LGSK-3. Among these, derivatives 11 and 17 exerted a
very good antileishmanial activity (GI50 < 0.76 μΜ in L.
donovani promastigotes and GI50 < 1.22 μΜ in L. dono-
vani intracellular amastigotes), and a good selectivity
index (>8). Compound 11 possessed the highest LGSK-3
over LCRK3 selectivity index (>33-fold). Thus, these com-
pounds are considered as an initial scaffold for the design
of LGSK-3 selective inhibitors and therefore for the design
of potent antileishmanial agents.
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